|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Diazoxide#Adult Indications and Dosage]] |
| {{Diazoxide}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Indications and Usage==
| |
| | |
| | |
| PROGLYCEM® (ORAL DIAZOXIDE) is useful in the management of [[hypoglycemia ]]due to [[hyperinsulinism]] associated with the following conditions:
| |
| | |
| Adults: Inoperable islet cell [[adenoma]] or [[carcinoma]], or [[extrapancreatic malignancy]].
| |
| | |
| Infants and Children: Leucine sensitivity, islet cell [[hyperplasia]], [[nesidioblastosis]], extrapancreatic malignancy, islet cell [[adenoma]], or adenomatosis. PROGLYCEM®may be used preoperatively as a temporary measure, and postoperatively, if [[hypoglycemia ]]persists.
| |
| | |
| | |
| PROGLYCEM® should be used only after a diagnosis of [[hypoglycemia]] due to one of the above conditions has been definitely established. When other specific medical therapy or surgical management either has been unsuccessful or is not feasible, treatment with PROGLYCEM® should be considered.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PROGLYCEM (DIAZOXIDE) SUSPENSION [TEVA GLOBAL RESPIRATORY RESEARCH LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b16c7832-2fd9-49af-b923-1dc0d91fd6e2 | publisher = | date = | accessdate = 26 February 2014 }}</ref>
| |
| | |
| | |
| ==References==
| |
| {{reflist|2}}
| |
| | |
| {{Nonsympatholytic vasodilatory antihypertensives}}
| |
| {{Other therapeutic products}}
| |
| {{Channel openers}}
| |
| | |
| [[Category:Sulfonamides]]
| |
| [[Category:Vasodilators]]
| |
| [[Category:Potassium channel openers]]
| |
| [[Category:Benzothiadiazines]]
| |
| [[Category:Organochlorides]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |